imexon
Small moleculeexperimental
Imexon is a substance that is being studied in the treatment of some types of cancer, including pancreatic, lung, breast, prostate, melanoma, and multiple myeloma. It is a cyanoaziridine derivative. — Wikipedia
Clinical trial activity
8 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2004 (NCT00327327)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 1
- Burkitt Lymphoma · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 2
- Lymphoma · Phase 2
- Lymphoma, B-Cell, Marginal Zone · Phase 2
- Lymphoma, Follicular · Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 2
- Lymphoma, Mantle-Cell · Phase 2
- Melanoma · Phase 1/Phase 2
- Multiple Myeloma · Phase 1/Phase 2
- Neoplasm Metastasis · Phase 1
- Pancreatic Neoplasms · Phase 2
- Prostatic Neoplasms · Phase 1
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
N=C1NC(=O)N2CC12- Mol. weight
- 111.1 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaImexon ↗
- ChEMBLCHEMBL146428 ↗
Also known as
- 4-amino-1,3-diazabicyclo(3.1.0)hex-3-en-2-one
- 4-imino-1,3-diazabicyclo(3.1.0)hexan-2-one
- amplimexon
- amplimexon
- bm 06002
- bm-06002
- imexon
- imexon
- imexon
- imexon
- imexon
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01314014 | Phase 2 | May 1, 2011 | University of Arizona, University of Rochester |
| NCT00697060 | Phase 2 | Aug 1, 2010 | AmpliMed Corporation |
| NCT00637247 | Phase 2 | Apr 1, 2008 | AmpliMed Corporation, Temple University |
| NCT00327223 | Phase 1 | Nov 1, 2005 | AmpliMed Corporation |
| NCT00327288 | Phase 1 | Oct 1, 2005 | AmpliMed Corporation |
| NCT00327249 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2005 | AmpliMed Corporation |
| NCT00327600 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2005 | AmpliMed Corporation |
| NCT00327327 | Phase 1 | Feb 1, 2004 | AmpliMed Corporation, Temple University, University of Michigan |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AmpliMed Corporation | For profit | 7 | 7 | 2 | 2004 |
| Temple University | Academic/Hospital | 2 | 0 | 2 | 2004 |
| University of Arizona | Academic/Hospital | 1 | 0 | 1 | 2011 |
| University of Michigan | Academic/Hospital | 1 | 0 | 1 | 2004 |
| University of Rochester | Academic/Hospital | 1 | 1 | 1 | 2011 |
5 organizations
Page 1 / 1